Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-12-3
pubmed:abstractText
The aim of this study was to investigate whether the VKORC1*3 (rs7294/9041 G?>?A), VKORC1*4 (rs17708472/6009 C?>?T), and CYP4F2 (rs2108622/1347 C?>?T) polymorphisms were associated with elevated warfarin maintenance dose requirements in patients with myocardial infarction (n = 105) from the Warfarin Aspirin Reinfarction Study (WARIS-II). We found significant associations between elevated warfarin dose requirements and VKORC1*3 and VKORC1*4 polymorphisms (P = .001 and P = .004, resp.), whereas CYP4F2 (1347 C?>?T) showed a weak association on higher warfarin dose requirements (P = .09). However, analysing these variant alleles in a regression analysis together with our previously reported data on VKORC1*2, CYP2C9*2 and CYP2C9*3 polymorphisms, gave no significant associations for neither VKORC1*3, VKORC1*4 nor CYP4F2 (1347 C?>?T). In conclusion, in patients with myocardial infarction, the individual contribution to warfarin dose requirements from VKORC1*3, VKORC1*4, and CYP4F2 (1347 C?>?T) polymorphisms was negligible. Our results indicate that pharmacogenetic testing for VKORC1*2, CYP2C9*2 and CYP2C9*3 is more informative regarding warfarin dose requirements than testing for VKORC1*3, VKORC1*4, and CYP4F2 (1347 C?>?T) polymorphisms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1110-7251
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
2011
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
739751
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction.
pubmed:affiliation
Department of Pharmacology, Oslo University Hospital, Ullevål, Oslo, Norway. m.k.kringen@medisin.uio.no
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't